

## AACR 2024: Brenus Pharma unveils promising and robust pre-clinical efficacy extrapolating human conditions with **STC-1010**<sup>1</sup>.

**STC-1010 vaccine demonstrated a strong batch to batch reproducibility of the immune response and tumor killing in multiple preclinical models with good safety profile.**

**Lyon, April 9, 2024** – Brenus Pharma unveils groundbreaking results during the [American Association Cancer Research](#) (AACR) Annual meeting 2024 – San Diego (April 5-10).

**“Efficacy of the STC-1010 a new allogeneic cancer vaccine in different colorectal cancer models”** | Abstract 5003 <https://doi.org/10.1158/1538-7445.AM2024-5003>

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.

STC-1010 was tested in several models extrapolating human conditions (*ex-vivo*; *in-ovo*,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with *in-ovo* model.

Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.

---

<sup>1</sup> STC-1010 is a next-generation cancer immunotherapy produced by allogeneic STC's proprietary Brenus platform. It's specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication.

- George ALZEEB<sup>2</sup>, [galzeeb@brenus-pharma.com](mailto:galzeeb@brenus-pharma.com), Innovation Manager Manager (*Ph.D*)
- Céline GONGORA<sup>3</sup>, [celine.gongora@inserm.fr](mailto:celine.gongora@inserm.fr), Research Director, Head of Team Inserm U1194 “Drug resistances and new cancer treatment” (*Ph.D*)
- Corentin RICHARD<sup>4</sup>, [CRichard@cgfl.fr](mailto:CRichard@cgfl.fr), Postdoctoral Bioinformatician (*Ph.D*)
- Romain BOIDOT<sup>3</sup>, [rboidot@cgfl.fr](mailto:rboidot@cgfl.fr), Molecular Biologist (*Ph.D*)
- Tanguy FORTIN<sup>5</sup>, [tanguy.fortin@anaquant.com](mailto:tanguy.fortin@anaquant.com), Chief Executive Officer (*Ph.D*)
- Yan WANG<sup>6</sup>, [yan.wang@inovotion.com](mailto:yan.wang@inovotion.com), Scientist/R&D Project Manager (*Ph.D*)
- Alban BESSEDE<sup>7</sup>, [a.bessede@explicyte.com](mailto:a.bessede@explicyte.com), Chief Executive Officer (*Ph.D*)
- Benoit PINTEUR<sup>1</sup>, [bpinteur@brenus-pharma.com](mailto:bpinteur@brenus-pharma.com), Chief Scientific Officer (*Pharm D*)
- Lionel CHALUS<sup>1</sup>, [lchalus@brenus-pharma.com](mailto:lchalus@brenus-pharma.com), Head of Technical Operation
- Corinne TORTORELLI<sup>1</sup>, [ctortorelli@brenus-pharma.com](mailto:ctortorelli@brenus-pharma.com), Senior Medical Lead (*Pharm.D., Ph.D*)
- Paul BRAVETTI<sup>1</sup>, [pbravetti@brenus-pharma.com](mailto:pbravetti@brenus-pharma.com), Chief Executive Officer (*Pharm D, MSc*)
- François GHIRINGHELLI<sup>8</sup>, [FGhiringhelli@cgfl.fr](mailto:FGhiringhelli@cgfl.fr), Head of Team Inserm 1231 TIRECs «Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology (*M.D, PhD*)

## Contact

mbrun@brenus-pharma.com | (+33) 787768772

## About Brenus Pharma

Brenus Pharma develops first-in-class proteomic-driven immunotherapies for the treatment of solid tumors. Brenus developed the STC platform (Stimulated-Tumor-Cells), mimicking relapse conditions and allowing the education of the patient's immune system to fight the resistance mechanisms of tumor cells.

<https://www.brenus-pharma.com/> | Follow us on [LinkedIn](#)

---

<sup>2</sup> Brenus Pharma, Lyon, France,

<sup>3</sup> INSERM U1194 IRCM, Montpellier, France,

<sup>4</sup> CNRS 6302, Dijon, France,

<sup>5</sup> Anaquant, Lyon, France

<sup>6</sup> Inovotion, La Tronche, France,

<sup>7</sup> Explicyte, Bordeaux, France

<sup>8</sup> Inserm 1231 CGFL, Dijon, France